Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects (EPI01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03828084
Recruitment Status : Completed
First Posted : February 4, 2019
Last Update Posted : May 9, 2019
Sponsor:
Information provided by (Responsible Party):
EpiDestiny, Inc.

Brief Summary:
To study the pharmacokinetic profiles of decitabine and tetrahydrouridine (THU) from 3 modified release formulations in healthy subjects.

Condition or disease Intervention/treatment Phase
Healthy Drug: Decitabine Phase 1

Detailed Description:
This is an open-label, randomized, single-dose per period, four-period, crossover study to evaluate relative bioavailability of decitabine in three newly formulated THU and decitabine combination capsules in comparison to 3 capsules of THU followed 1 hour later by 3 capsules of decitabine.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Four-way crossover, single dose with a 7 days washout period in between periods
Masking: None (Open Label)
Primary Purpose: Other
Official Title: An Open-Label, Randomized, Single-Dose, Four-Way Crossover, Bioavailability Study of Three Formulations of Decitabine/Tetrahydrouridine (THU) Combination Modified Release Capsules (5 mg/250 mg) in Healthy and Fasting Adults
Actual Study Start Date : April 3, 2019
Actual Primary Completion Date : May 2, 2019
Actual Study Completion Date : May 3, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Decitabine

Arm Intervention/treatment
Experimental: Formulation A
3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation A) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
Drug: Decitabine
Combination drugs containing decitabine and tetrahydrouridine
Other Name: Tetrahydrouridine

Experimental: Formulation B
3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation B) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
Drug: Decitabine
Combination drugs containing decitabine and tetrahydrouridine
Other Name: Tetrahydrouridine

Experimental: Formulation C
3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation C) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
Drug: Decitabine
Combination drugs containing decitabine and tetrahydrouridine
Other Name: Tetrahydrouridine

Active Comparator: Reference Formulation
3 capsules of THU (250 mg per capsule) given as a single oral dose with approximately 240 mL of ambient temperature water, followed by a single oral dose of 3 capsules of decitabine (5 mg per capsule) given 1 hour later with approximately 240 mL of ambient temperature water.
Drug: Decitabine
Combination drugs containing decitabine and tetrahydrouridine
Other Name: Tetrahydrouridine




Primary Outcome Measures :
  1. Pharmacokinetics of Decitabine [ Time Frame: 24 hours ]
    Area under the concentration-time curve (AUC) from time of dosing to the last quantifiable concentration of Decitabine

  2. Decitabine plasma concentration [ Time Frame: 24 hours ]
    Maximum concentration (Cmax) of Decitabine in plasma

  3. Pharmacokinetics of Tetrahydrouridine [ Time Frame: 24 hours ]
    Area under the concentration-time curve (AUC) from time of dosing to the last quantifiable concentration of THU


Secondary Outcome Measures :
  1. Safety of Decitabine and Tetrahydrouridine [ Time Frame: 24 hours ]
    Safety of single dose as measured by adverse event reporting



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Must understand and voluntarily sign a written ICF prior to any study related procedures being performed and be able to adhere to restrictions and examination schedules.
  • Must be able to communicate with the investigator, and to understand and comply with the requirements of the study.
  • Healthy male volunteers from any race between 18 to 50 years of age (inclusive), and in good health as determined by past medical history, physical examination, vital signs, ECG, and laboratory tests at screening.
  • Must have a body mass index (BMI) between 18 and 30 kg/m2 (inclusive) and a weight between 60 and 100 kg (132 to 220 lb), inclusive, at screening.
  • Subject's clinical laboratory test results have no clinically significant findings, in the opinion of the Investigator.
  • Vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed in the supine position after the subject has rested for at least 5 minutes. At screening, the potential subject must be afebrile, with a systolic blood pressure between 90 and 140 mmHg (inclusive), diastolic blood pressure between 60 and 90 mmHg (inclusive), and pulse rate between 50 and 100 bpm (inclusive). Vital signs criteria at each check-in and the pre-dose measurements will be at the Investigator's discretion.
  • Subjects must be free of any clinically significant disease that would interfere with the study evaluations.
  • Subjects (including those who have had a documented vasectomy) must be using a double-barrier local contraception (i.e., spermicidal gel plus condom) when engaging in sexual activity with women of childbearing potential while on study medication and for 28 days after the last dose of study medication.
  • Subjects must refrain from sperm donations while on study drug, for the entire duration of the study, and for 28 days after the last dose of study drug.

Exclusion Criteria:

  • History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition, including the presence of laboratory abnormalities, that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results.
  • Any serious medical condition, clinically significant laboratory abnormality, or psychiatric illness that would prevent the subject from signing the ICF.
  • Recent history within 3 years of any clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological or other major disorders.
  • Used any prescribed systemic or topical medication within 30 days of the first dose administration.
  • Used any non-prescribed systemic (including herbal medicines, e.g. St. John's Wort) or topical medication within 7 days of the first dose administration (with the exception of vitamin/mineral supplements)
  • Subjects who have any surgical or medical conditions possibly affecting drug absorption, distribution, metabolism and excretion (ADME).
  • Exposed to an investigational drug (new chemical entity) within 90 days preceding the first dose administration or currently enrolled in any investigational trials.
  • Donated blood or plasma within 8 weeks preceding the first dose administration.
  • History of multiple drug allergies.
  • Any clinically significant allergic disease (excluding nonactive hay fever).
  • History of drug abuse of at least 2 years prior to dosing, or positive drug screening test due to illicit drugs.
  • History of alcohol abuse of at least 2 years prior to dosing, or positive alcohol screen.
  • Smokers or users of other tobacco products (e.g., chewing tobacco, or those using nicotine-containing products (i.e., patches, gum) in the 3 months prior to screening, or positive urine cotinine test.
  • Known to have serum hepatitis or known to be a carrier of the hepatitis B surface antigen (HBsAg) or hepatitis C antibody, or tests positive for HIV (human immunodeficiency virus) antibodies at screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03828084


Locations
Layout table for location information
United States, Texas
Worldwide Clinical Trial
San Antonio, Texas, United States, 78217
Sponsors and Collaborators
EpiDestiny, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Cynthia A Zamora, MD Worldwide Clinical Trials Early Phase Services, LLC

Additional Information:
Layout table for additonal information
Responsible Party: EpiDestiny, Inc.
ClinicalTrials.gov Identifier: NCT03828084     History of Changes
Other Study ID Numbers: EPI-01-CP.001
First Posted: February 4, 2019    Key Record Dates
Last Update Posted: May 9, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Decitabine
Tetrahydrouridine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors